OSOladimeji Emmanuel Soremekun

Oladimeji Emmanuel Soremekun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Oladimeji Emmanuel Soremekun has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hibiscus sabdariffa ameliorates tramadol-induced neurotoxicity via antioxidant, anti-inflammatory, anti-apoptotic, and neurotransmission-regulating mechanisms

    by Oladimeji Emmanuel Soremekun, Paul Ademola Adeleke, Leviticus Arietarhire, Ezekiel Abiola Olugbogi, Sunday Omirin, Clinton Ijirigho, Favour Boluwatife Jegede, Esther Toluwalope Ojo, Oyetola Oyebanjo, Abayomi Mayowa Ajayi, et al.

    Introduction: The misuse and abuse of tramadol, a synthetic opioid analgesic, has become a major public health concern in Africa. Although effective for managing moderate to severe pain, tramadol exposure has been associated with central nervous system toxicity. Hibiscus sabdariffa , commonly consumed as “Zobo,” contains bioactive substances with potent antioxidant and anti-inflammatory properties. Therefore, this study investigated the neuroprotective potential of aqueous H. sabdariffa extract (HSE) against tramadol-induced neurotoxicity in male Swiss mice. Methodology: Fifty adult male mice were randomly assigned into five groups namely control (normal saline), tramadol (50 mg/kg), and three treatment groups receiving tramadol intraperitoneally plus HSE given through oral route at 50, 100, and 200 mg/kg for 21 days. Neurobehavioral tests assessed motor coordination, cognition, anxiety, and depressive-like behaviors. Brain regions, including the hippocampus, prefrontal cortex, and cerebellum, were analyzed for malondialdehyde, reduced glutathione, catalase, superoxide dismutase, glutathione-S-transferase, nitrite levels, acetylcholinesterase activity, and pro-inflammatory cytokines, including interleukin-6, and tumour necrosis factor-alpha. Histological analysis was performed using Nissl staining, while RT-PCR quantified neurotransmission- and apoptosis-related genes, including GAD2, TH, TP53, BAX, and BCL-2. Molecular docking evaluated interactions of H. sabdariffa phytocompounds with target proteins. Results: Tramadol exposure significantly impaired behavior, increased oxidative stress and inflammation, depleted antioxidant defenses, and induced neuronal damage with altered gene expression. H. sabdariffa extract treatment dose-dependently mitigated these alterations, preserved neuronal architecture, and modulated apoptosis-related genes. Docking computation identified Quercetin-3-O-rutinoside, Baicalin, and Delphinidin-3-O-sambubioside as hit compounds with strong binding affinity to target proteins of the genes evaluated in the RT-PCR. Conclusion: Hibiscus sabdariffa aqueous extract activity suggests robust neuroprotective effects against tramadol-induced neurotoxicity through coordinated antioxidant, anti-inflammatory, anti-apoptotic, and neuromodulatory mechanisms. These findings position H. sabdariffa extract as a promising, accessible therapeutic candidate for managing opioid-induced CNS damage.

  • Open Access

    EXPLORING ANTIHYPERTENSIVE DRUG LEADS FROM BLIGHIA SAPIDA K. D. KOENIG VIA GC-MS AND IN SILICO APPROACHES

    by Comfort Titilayomi Senjobi, Daniel Oriola Shokoya, Oladimeji Emmanuel Soremekun, Abimbola Heritage Senjobi, Ezekiel Abiola Olugbogi, Olubukola Iretiola Lawal, Olaitan Chinenye Okechukwu, Afui Olugbenga Ettu, Muhali Olaide Jimoh, Samuel Oloruntoba Bamigboye, et al.

    Globally, hypertension is a leading cause of cardiovascular diseases that account for around 17 million deaths. Despite more studies and management measures, the cause of hypertension is barely unknown, auxiliary antihypertensive medications have some drawbacks which include high prices, adverse effects, and resistivity. The little or no side effects posed by alternative medicines and patient compliance to medicinal plants raised interest in investigating Blighia sapida K. D. Koenig (Ackee) for its bioactive agents including proteins that could be responsible for its antihypertensive properties. Ethanol leave extract was analyzed using gas chromatography-mass spectrometry (GC-MS) analysis to detect the various bioactive compounds, two proteins that play prominent roles in hypertension were studied and retrieved for Molecular Docking using 3D crystal structures, wizard module of Schrödinger Maestro 12.8 employed to prepare the protein. The results of the docking computations were cleaned and analyzed using Excel spreadsheet software. Following receptor and ligand preparation, molecular docking computations were conducted using Glide's ligand docking plugin with extra precision docking to rigorously score ligand-protein interactions. Further graphical representations of the docking results were created using the R Studio package and GraphPad Prism V8.0. Visualization of the molecular interactions of the ligand-protein complexes was conducted. The GC-MS identified a total of 33 compounds in the ethanol extract: Benzenecarboximidothioic acid, N-phenyl-, 4-nitrophenyl ester, N-Serylserine and Palmitic Acid among others. During molecular docking, in-silico pharmacokinetics, and toxicological profiling, serylserine and pirenzepine were identified for their potential interactions with other important proteins related to hypertension including the calcium ion channel and the angiotensin II receptor (ARB). Serylserine and pirenzepine showed potential binding energy against the targeted proteins. This study could produce new antihypertensive medications that are less expensive, more widely available, and less likely to cause adverse effects, thereby meeting public health requirements, particularly in poor nations.

  • Open Access

    Genetic Associations and Functional Pathways in Parkinson's Disease: A Meta-Analytic Insight into LRRK2 Mutation Impact

    by John A.Olanrewaju, Ambrose George Oche, Leviticus Arietarhire, Tolu Afolabi, Ezekiel Olugbogbi, Enya Joseph, Oladimeji Somerekun, Joel Irewoluwa, Alessi Dario, Rotimi Fasimoye, et al.

    Background: Parkinson's Disease (PD) is a complex neurodegenerative disorder with elusive pathophysiological mechanisms. Recent studies have highlighted the role of genetic variations and metabolic changes in PD progression. Aim: This study aims to investigate the genetic disparities in PD, particularly focusing on LRRK2 mutations, and to analyze the associated metabolic pathway alterations. Methodology: The study utilized R programming with MetaIntegrator for meta-analysis and ggplot2 for visualization. Datasets underwent preprocessing, and the MetaIntegrator package computed meta scores, effects, and ROC analysis. Differential gene expression and functional enrichment analyses provided insights into genetic associations and pathways in Parkinson's disease and LRRK2 mutations. Results: Significant meta-score differences were observed in PD patients, especially in datasets GSE133347, GSE36321, and GSE100054, underscoring the impact of LRRK2 mutations. Genes like SKAP2 and IFNGR2 were significantly upregulated, implicating their role in neuroinflammation. Moreover, a shift in metabolic pathways, particularly carbohydrate kinase activity, was noted, indicating altered energy metabolism in PD cells. Conclusion: The study reinforces the genetic heterogeneity of PD and highlights the potential therapeutic importance of targeting neuroinflammatory pathways and metabolic dysfunctions. These findings suggest new avenues for diagnostic and therapeutic strategies in PD management.

  • Open Access

    Spondias mombin flavonoids showed super-binder ability with Downstream Molecular Targets of Parkinson’s Disease: Folkloric-therapy assessment as a Scaffold for Structural Studies in Neurodegenerative disease

    by John A. Olanrewaju, Leviticus O. Arietarhire, Oladimeji E. Soremekun, Ezekiel A. Olugbogi, Toluwanimi O. Afolabi, Babatunji E. Oyinloye, Olaposi I. Omotuyi, Steven Russell

    Spondias mombin (S. mombin), a prominent botanical resource, has garnered recognition within folkloric therapy. Parkinson's disease (PD), characterized by dopaminergic neuron attrition in the substantia nigra, manifests as motor anomalies like tremors, rigidity, and bradykinesia. This study capitalizes on S. mombin's reservoir of 100 characterized phytocompounds and employs computational methodologies to interrogate their potential 35 PD-associated target proteins. Employing a multifaceted approach, we engaged in molecular docking, ADMET predictions, Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) evaluations, Density Functional Theory (DFT), and Molecular Dynamic Simulations (MDS). This comprehensive framework facilitated insightful structural assessments and predictive analyses. Impressively, flavonoids hailing from S. mombin, including quercetin, catechin, ellagic acid, and epicatechin, showcased optimal binding affinities for PD-relevant target proteins. Moreover, these identified ligands exhibited minimal signs of mutagenicity, tumorigenicity, or irritancy, except for quercetin, which displayed elevated tumorigenic potential. Notably, quercetin and dopamine exhibited varying band gap energies, with quercetin the lowest (3.63 eV) and dopamine the highest (5.76 eV) values. MDS result suggests a synergistic outcome based on the RMSD and RMSF graphs for quercetin highlighting it as the best of all including the co-ligand. In a collective sense, our findings present S. mombin as promising reservoirs of active pharmaceutical ingredients, warranting further exploration for novel PD therapeutic avenues. Consequently, this study underscores the enhanced efficacy of phyto-ligands sourced from S. mombin, advocating their optimization as potential drug candidates.


  • Vernonia amygdalina Alleviates Neurodegenerative Effects of High Fat Diet and Streptozotocin-Induced Type 2 Diabetes Mellitus in the Hippocampi of Adult Male Wistar Rats

    by Olanrewaju John Afees, Ekundayo Ifeoluwa Olufunmilola, Adeniji Kehinde Oluwaseyi, Enya Joseph Igbo, Leviticus Arietarhire, Oladimeji Soremekun, Olubunmi Ogunbiyi, Richard Bamidele, Adelodun Stephen Taiye, Olatunji Sunday Yinka, et al.

    Cognitive impairment and neurodegeneration are a few hallmarks of brain insulin resistance, a core feature of Type 2 diabetes mellitus (T2DM). Using a Wistar rat model of a high-fat diet and streptozotocin-induced T2DM, we aimed to determine the potential of Vernonia amygdalina (VA) as a possible treatment for the accompanied neurodegenerative effects of this condition on hippocampal structure and function. T2DM adult rats were prepared by a combination of a high-fat diet and intraperitoneal injection of 35 mg/kg streptozocin. The elevated plus and Barnes maze tests were used to evaluate anxiety, learning, and memory functions, followed by H&E and cresyl violet staining, immunohistochemical staining for hippocampal amyloid beta, synaptophysin, and glial fibrillary acid protein (GFAP), and RNA analysis of P53, P21, glutathione (GSH) and glutathione peroxidase (GPX-1) genes expression levels. T2DM model animals had significantly reduced open arm entries and duration and higher escape latencies, depicting increased anxiety and decreased spatial memory and learning abilities(P<0.05). Expression changes were evident for P53, GSH, P21, and GPX-1 genes, which included an increased expression of P53 and P21 in the hippocampus of T2DM model animals and a slight reduction of these genes in VA groups, and an increased expression of GSH in T2DM and VA groups. Also, photomicrographs revealed a fragmented pyramidal cell layer with visible pyknotic cells and a gross reduction in cytoplasmic Nissl proteins across the Cornus Ammonis and dentate gyrus regions of the hippocampi. Similarly, increased expression of amyloid-beta, synaptophysin, and GFAP was seen in these regions. However, V. amygdalina was able to enhance the learning and memory abilities of T2DM rats, replenish hippocampal pyramidal neurons, and help improve hippocampal synapses, while improving the brain’s antioxidant defense system. These findings may provide helpful insights into the treatment of T2DM-induced brain insulin resistance.

  • Repurposing Nandrolone, an Anabolic Steroid drug for Cancer Therapeutics: An In silico approach

    by Oladimeji Soremekun

    Finding novel drugs and repurposing existing ones have gained increasing attention in addressing various setbacks faced by researchers in cancer research and treatment owing to the increased cancer rate, low efficacy, availability, and affordability of cancer drugs. Thus, the goal of this research is to repurpose nandrolone (ND), an inexpensive and widely available anabolic steroid, to a potential anticancer therapeutic candidate. A computer-aided drug design approach (CADD) involving virtual screening was used to obtain the binding scores (kcal/mol) and inhibiting efficiencies (IC50 µ/mol ) of ND against DNA Topoisomerase II Alpha (TOP2A), Cyclin D1, Cyclin-dependent kinases IV & VI (CDK4/6) and cancer cell lines (HEPG2, MHHNB11, SW1573, and SNU245) by employing PyRx, Pymol, Discovery studio, and PaccMann web tool. Data warrior tool and SwissADME online tool were used to conduct in silico pharmacokinetic studies involving drug-likeness and ADMET profiling of ND. The findings of these analyses were compared with the conventional (standard) cancer medicines (doxorubicin, palbociclib). Results of this study showed ND had a higher binding affinity for TOP2A, CDK4, and CDK6 with binding scores of -74kcal/mol; -5.9kcal/mol; and -9.4kcal/mol when docked into the binding pockets of three of the four proteins in comparison with that of the standards. Furthermore, it exhibited a high level of inhibitory activity against cancer cell lines with an average IC50= 0.55 and demonstrated good pharmacokinetics as it possesses the required ADMET (absorption, distribution, metabolism, excretion, and toxicity) criteria. In keeping with the findings from this study, nandrolone shows promising potential as an anticancer drug candidate. However, further studies using in vitro and animal models should be conducted to elucidate the underlying mechanisms of nandrolone in combating cancer.